Latest Press Releases
- 09/06/2011 TESARO Named A 2011 Fierce 15 Company
- 06/21/2011 TESARO Announces $101 Million Series B Financing
- 03/22/2011 TESARO In-Licenses ALK Program from Amgen
- 12/14/2010 TESARO In-Licenses Rolapitant from OPKO
Who We Are
We are a team of associates who strive to be responsive to the needs of cancer patients. From this grows our determination to offer better health and more hope for those who live with cancer. Read More →
TESARO is a privately held oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by developing and commercializing safer and more effective therapeutics. TESARO is headquartered in Boston, Massachusetts.